TY - JOUR
T1 - Minimal/measurable residual disease in AML
T2 - a consensus document from the European LeukemiaNet MRD Working Party
AU - Schuurhuis, Gerrit J.
AU - Heuser, Michael
AU - Freeman, Sylvie
AU - Béne, Marie Christine
AU - Buccisano, Francesco
AU - Cloos, Jacqueline
AU - Grimwade, David
AU - Haferlach, Torsten
AU - Hills, Robert K.
AU - Hourigan, Christopher S.
AU - Jorgensen, Jeffrey L.
AU - Kern, Wolfgang
AU - Lacombe, Francis
AU - Maurillo, Luca
AU - Preudhomme, Claude
AU - van der Reijden, Bert A.
AU - Thiede, Christian
AU - Venditti, Adriano
AU - Vyas, Paresh
AU - Wood, Brent L.
AU - Walter, Roland B.
AU - Döhner, Konstanze
AU - Roboz, Gail J.
AU - Ossenkoppele, Gert J.
N1 - Publisher Copyright:
Copyright 2011 by The American Society of Hematology; all rights reserved.
PY - 2018/3/22
Y1 - 2018/3/22
N2 - Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and molecular data assessed at diagnosis. MRD can be evaluated using a variety of multiparameter flow cytometry and molecular protocols, but, to date, these approaches have not been qualitatively or quantitatively standardized, making their use in clinical practice challenging. The objective of this work was to identify key clinical and scientific issues in the measurement and application of MRD in AML, to achieve consensus on these issues, and to provide guidelines for the current and future use of MRD in clinical practice. The work was accomplished over 2 years, during 4 meetings by a specially designated MRD Working Party of the European LeukemiaNet. The group included 24 faculty with expertise in AML hematopathology, molecular diagnostics, clinical trials, and clinical medicine, from 19 institutions in Europe and the United States.
AB - Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and molecular data assessed at diagnosis. MRD can be evaluated using a variety of multiparameter flow cytometry and molecular protocols, but, to date, these approaches have not been qualitatively or quantitatively standardized, making their use in clinical practice challenging. The objective of this work was to identify key clinical and scientific issues in the measurement and application of MRD in AML, to achieve consensus on these issues, and to provide guidelines for the current and future use of MRD in clinical practice. The work was accomplished over 2 years, during 4 meetings by a specially designated MRD Working Party of the European LeukemiaNet. The group included 24 faculty with expertise in AML hematopathology, molecular diagnostics, clinical trials, and clinical medicine, from 19 institutions in Europe and the United States.
UR - http://www.scopus.com/inward/record.url?scp=85047630537&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047630537&partnerID=8YFLogxK
U2 - 10.1182/blood-2017-09-801498
DO - 10.1182/blood-2017-09-801498
M3 - Article
C2 - 29330221
AN - SCOPUS:85047630537
SN - 0006-4971
VL - 131
SP - 1275
EP - 1291
JO - Blood
JF - Blood
IS - 12
ER -